Vaxart Stock News

The goal: a portfolio that should pay off well into the future.

As the Covid-19 vaccine maker expands into a second manufacturing facility, VXRT stock remains an undervalued gem. The post Vaxart Deserves More Respect on Wall Street for Its Promising Covid-19 Vacci

They've strongly outperformed the market in the past, and they could easily do it again.

They've strongly outperformed the market in the past, and they could easily do it again.

Vaxart, Inc. (NASDAQ:VXRT)s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $7.62 and traded as low as $6.41. Vaxart shares last traded at $7.20, with a volume of 9,325,846 shares trading hands. A number of equities research analysts []

Vaxart Inc. (NASDAQ: VXRT) shares were trading higher Friday after the company plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the omicron SARS-CoV-2 variant

Vaxart Inc. (NASDAQ: VXRT ) shares were trading higher Friday after the company plans to test the cross-reactivity of its…

Vaxart Inc. (NASDAQ:VXRT) shares were trading higher Friday after the company plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the omicron SARS-CoV-2 variant i

NEW YORK , Dec. 17, 2021 /PRNewswire/ -- The ongoing pandemic is causing renewed concerns as new variants are becoming more prominent. As an example, test positivity rates in New York City have doubled in just three days, Dr. Jay Varma , a top health advisor to Mayor Bill de Blasio , tweeted Thursday. According to data provided by the CDC on Wednesday, New York and New Jersey are the two states with the most rapid spread of the Omicron variant. To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC''s national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local public health laboratories. In the meantime, restrictions for private businesses have become more strict. Todos Medical Ltd. (OTC: TOMDF ), Pfizer Inc. (NYSE: PFE ), Johnson & Johnson (NYSE: JNJ ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Vaxart, Inc. (NASDAQ: VXRT ) As a result of the most recent surge, schools like New York University and Cornell University have canceled in-person events and shifted finals online.

Cross-reactivity will be assessed using samples from Phase II clinical participants and in a parallel animal challenge study

Revenue could skyrocket at these healthcare companies.

Select analysts and investment banks see these fast-paced stocks soaring next year.

Select analysts and investment banks see these fast-paced stocks soaring next year.

Vaxart, Inc. (NASDAQ:VXRT) B. Riley decreased their FY2021 earnings estimates for shares of Vaxart in a research report issued to clients and investors on Monday, December 6th. B. Riley analyst M. Mamtani now expects that the biotechnology company will earn ($0.59) per share for the year, down from their prior forecast of ($0.56). B. []